Meiji Pharmaceutical University | Japan
Shinobu Hirayama is a Japanese clinical microbiology researcher and pharmacist whose work focuses on antimicrobial stewardship, antimicrobial resistance, and clinical infectious diseases. She holds a Bachelor of Pharmacy from Meiji Pharmaceutical University (1997) and is currently pursuing a PhD in Microbiology. With long-standing experience at Toho University Omori Medical Centre—most recently as Assistant Director of the Department of Pharmacy—she has contributed extensively to infection control and antimicrobial management. Her research portfolio includes peer-reviewed publications on carbapenem-resistant Enterobacterales, antimicrobial dosing metrics, vancomycin-associated kidney injury, and therapeutic strategies for COVID-19 and Clostridioides difficile. She has presented her work at major national and international conferences, including APSMM. Hirayama’s scholarly output includes 5 peer-reviewed documents, cited by 122 documents, with an h-index of 2, reflecting her growing impact in clinical microbiology and antimicrobial stewardship research. She received the Encouragement Award from the Japanese Society of Chemotherapy (2016) for developing a novel evaluation method for carbapenem stewardship. Her current work aims to refine antimicrobial and antifungal stewardship practices to improve patient outcomes and limit resistance development.
Featured Publications
Ohtani, M., Yokoo, T., Miyazaki, T., Yasuda, H., Nishikawa, E., Tomida, M., Tsukada, M., Sato, E., Hirayama, S., Murakami, H., Yoshizawa, S., Matsumoto, T., & Tateda, K.
“Clinical efficacy of casirivimab and imdevimab in preventing COVID-19 in the Omicron BA.5 subvariant epidemic: a retrospective study” in Journal of Pharmaceutical Health Care and Sciences, 11(1): 94.
Hirayama, S., Otani, M., Murakami, H., Sakamoto, M., Tateda, K., Matsumoto, T., & Sugita, T. “Association between antimicrobial use and the detection rates of carbapenem-resistant Enterobacterales: long-term surveillance results from a single centre” in Infection Prevention in Practice, In Press.
Ohtani, M., Yoshizawa, S., Miyazaki, T., Kumade, E., Hirayama, S., Sakamoto, M., Murakami, H., Maeda, T., Ishii, Y., Matsumoto, T., & Tateda, K. “Clinical efficacy of therapeutic agents for Clostridioides difficile infection based on four severity classifications” in Japanese Journal of Infectious Diseases, 77(5): 281–284.
Uekusa, S., Hanai, Y., Hirayama, S., Yokoo, T., Hasegawa, T., Shimoyama, K., Kusano, A., Nishizawa, K., Matsumoto, T., & Matsuo, K. “Vancomycin hydrochloride as a risk factor for acute kidney injury: a retrospective study” in Pharmacology, 108(5): 444–450.